» Articles » PMID: 34278265

Extensive Three-dimensional Intratumor Proteomic Heterogeneity Revealed by Multiregion Sampling in High-grade Serous Ovarian Tumor Specimens

Abstract

Enriched tumor epithelium, tumor-associated stroma, and whole tissue were collected by laser microdissection from thin sections across spatially separated levels of ten high-grade serous ovarian carcinomas (HGSOCs) and analyzed by mass spectrometry, reverse phase protein arrays, and RNA sequencing. Unsupervised analyses of protein abundance data revealed independent clustering of an enriched stroma and enriched tumor epithelium, with whole tumor tissue clustering driven by overall tumor "purity." Comparing these data to previously defined prognostic HGSOC molecular subtypes revealed protein and transcript expression from tumor epithelium correlated with the differentiated subtype, whereas stromal proteins (and transcripts) correlated with the mesenchymal subtype. Protein and transcript abundance in the tumor epithelium and stroma exhibited decreased correlation in samples collected just hundreds of microns apart. These data reveal substantial tumor microenvironment protein heterogeneity that directly bears on prognostic signatures, biomarker discovery, and cancer pathophysiology and underscore the need to enrich cellular subpopulations for expression profiling.

Citing Articles

Quantifying intratumoral biomarker heterogeneity in tubo-ovarian high-grade serous carcinoma to optimize clinical translation.

Talhouk A, Chiu D, Meunier L, Rahimi K, Le Page C, Bernard M Sci Rep. 2025; 15(1):2459.

PMID: 39828752 PMC: 11743601. DOI: 10.1038/s41598-024-82206-z.


Challenges in Implementing Comprehensive Precision Medicine Screening for Ovarian Cancer.

Moffitt L, Karimnia N, Wilson A, Stephens A, Ho G, Bilandzic M Curr Oncol. 2024; 31(12):8023-8038.

PMID: 39727715 PMC: 11674382. DOI: 10.3390/curroncol31120592.


dia-PASEF Proteomics of Tumor and Stroma LMD Enriched from Archived HNSCC Samples.

Panigrahi A, Hunt A, Assis D, Willetts M, Kallakury B, Davidson B bioRxiv. 2024; .

PMID: 39149249 PMC: 11326218. DOI: 10.1101/2024.08.09.607341.


Quantitative proteomic analysis of HER2 protein expression in PDAC tumors.

Randall J, Hunt A, Nutcharoen A, Johnston L, Chouraichi S, Wang H Clin Proteomics. 2024; 21(1):24.

PMID: 38509475 PMC: 10953162. DOI: 10.1186/s12014-024-09476-7.


Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities.

Bateman N, Abulez T, Soltis A, McPherson A, Choi S, Garsed D NPJ Precis Oncol. 2024; 8(1):68.

PMID: 38480868 PMC: 10937683. DOI: 10.1038/s41698-024-00519-8.


References
1.
Baldelli E, Bellezza G, Haura E, Crino L, Cress W, Deng J . Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors. Oncotarget. 2015; 6(32):32368-79. PMC: 4741699. DOI: 10.18632/oncotarget.5941. View

2.
Leong H, Galletta L, Etemadmoghadam D, George J, Kobel M, Ramus S . Efficient molecular subtype classification of high-grade serous ovarian cancer. J Pathol. 2015; 236(3):272-7. DOI: 10.1002/path.4536. View

3.
Bu L, Baba H, Yoshida N, Miyake K, Yasuda T, Uchihara T . Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment. Oncogene. 2019; 38(25):4887-4901. DOI: 10.1038/s41388-019-0765-y. View

4.
Schwede M, Waldron L, C Mok S, Wei W, Basunia A, Merritt M . The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2019; 29(2):509-519. PMC: 7448721. DOI: 10.1158/1055-9965.EPI-18-1359. View

5.
Rossi L, Verrico M, Zaccarelli E, Papa A, Colonna M, Strudel M . Bevacizumab in ovarian cancer: A critical review of phase III studies. Oncotarget. 2016; 8(7):12389-12405. PMC: 5355353. DOI: 10.18632/oncotarget.13310. View